March 28th, 2014
ACC.14 Headquarters
wpengine
CardioExchange is dedicated to bringing you the latest from ACC.14. Check out our coverage of the conference ─ and some of the great debates these posts have sparked ─ then tell us what you think!
News:
Analysis:
Follow our Fellows:
NEJM — Recent Cardiology Articles- Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome March 5, 2026A CD19-targeted therapy induced remission in a woman with refractory immune thrombocytopenia and antiphospholipid syndrome by stabilizing platelet counts, eliminating pathogenic antibodies, and enabling safer long-term anticoagulation.
- Assessing Nonculprit Coronary-Artery Lesions in STEMI March 5, 2026Multivessel coronary artery disease is seen on invasive coronary angiography in approximately 50% of patients presenting with acute ST-segment elevation myocardial infarction (STEMI). Previous trials have shown that in patients with hemodynamically stable disease, revascularization with percutaneous coronary intervention (PCI) of a nonculprit coronary lesion results in better outcomes than...
- Blood-Pressure Targets in Hypertension Management March 5, 2026This feature about blood-pressure targets to manage hypertension offers a case vignette accompanied by two essays, one recommending a systolic blood-pressure target of less than 120 mm Hg and the other supporting a target of less than 140 mm Hg.
- Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction March 5, 2026In STEMI with multivessel disease, immediate iFR-guided PCI of nonculprit lesions was not superior to deferred cardiac stress MRI–guided PCI in reducing death, reinfarction, or hospitalization for heart failure at 3 years.
- An Incidental Finding Unraveled February 26, 2026When a physician’s own incidental finding sends her down a long and winding path to find answers, she finds herself overcome with worry — but also, eventually, a new appreciation for life.
- Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome March 5, 2026